selenium has been researched along with etoposide in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Baker, AF; Berggren, MI; Gallegos, A; Husbeck, B; Powis, G; Samulitis, B | 1 |
Amess, J; Cornelius, V; Delves, T; Fitzgibbon, J; Last, KW; Lister, TA; Norton, A; Rohatiner, AZ; Sieniawska, C; Wilson, A | 1 |
Al-Bader, MM; Khan, KM; Kilarkaje, N; Mousa, AM | 1 |
Al-Bader, M; Kilarkaje, N | 1 |
Kilarkaje, N | 1 |
Hassan, YF; Khalaf, HA; Moustafa, AM; Omar, NM; Sakkara, ZA | 1 |
6 other study(ies) available for selenium and etoposide
Article | Year |
---|---|
Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin.
Topics: Animals; Antioxidants; Apoptosis; Base Sequence; Dexamethasone; DNA Primers; Doxorubicin; Etoposide; Female; Gene Expression; Humans; Hydrogen Peroxide; Mice; Neoplasm Proteins; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Selenium; Thioredoxins; Transfection; Tumor Cells, Cultured | 2001 |
Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leucovorin; Linear Models; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Retrospective Studies; Selenium; Survival Analysis; Vincristine | 2003 |
Antioxidants enhance the recovery of three cycles of bleomycin, etoposide, and cisplatin-induced testicular dysfunction, pituitary-testicular axis, and fertility in rats.
Topics: alpha-Tocopherol; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Atrophy; Bleomycin; Blotting, Western; Cisplatin; Cytoprotection; Disease Models, Animal; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Fertility; Hormones; Immunohistochemistry; Male; Pituitary Gland; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Recovery of Function; Selenium; Sperm Count; Sperm Motility; Spermatogenesis; Testicular Diseases; Testis; Time Factors; Transferrin; Zinc | 2013 |
Effects of antioxidants on drugs used against testicular cancer-induced alterations in metastasis-associated protein 1 signaling in the rat testis.
Topics: Actins; alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Ascorbic Acid; Bleomycin; Cisplatin; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Etoposide; Histone Deacetylases; Male; Proteins; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Selenium; Signal Transduction; Testicular Neoplasms; Testis; Up-Regulation | 2016 |
Effects of combined treatment of α-tocopherol, L-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats.
Topics: alpha-Tocopherol; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Bleomycin; Blotting, Western; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Etoposide; Male; Rats; Rats, Sprague-Dawley; Selenium; Testosterone; Time Factors; Up-Regulation; Zinc | 2014 |
Comparative study of the ameliorative effects of omega-3 versus selenium on etoposide-induced changes in Sertoli cells and ectoplasmic specialization of adult rat testes: immunohistochemical and electron microscopic study.
Topics: Animals; Electrons; Etoposide; Male; Rats; Selenium; Sertoli Cells; Testis; Vimentin | 2022 |